<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Loop diuretics: Dosing and major side effects</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Loop diuretics: Dosing and major side effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Loop diuretics: Dosing and major side effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">D Craig Brater, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David H Ellison, MD, FASN, FAHA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Emmett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Loop diuretics reduce sodium chloride reabsorption in the thick ascending limb of the loop of Henle. This is achieved by inhibiting the Na-K-2Cl carrier in the luminal membrane in this segment, thereby minimizing the entry of luminal sodium and chloride into the cell (<a class="graphic graphic_figure graphicRef75301" href="/z/d/graphic/75301.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. The loop diuretics are highly protein bound and therefore enter the tubule primarily by secretion in the proximal tubule, rather than by glomerular filtration [<a href="#rid1">1</a>].</p><p>The most commonly used loop diuretics are <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>, <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a>, and <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>, which are sulfonamide derivatives. <a class="drug drug_general" data-topicid="9429" href="/z/d/drug information/9429.html" rel="external">Ethacrynic acid</a> is rarely used but is an alternative in patients who have a hypersensitivity reaction to a typical loop diuretic. (See <a class="local">'Hypersensitivity reactions'</a> below.)</p><p>Intravenous loop diuretic treatment is commonly employed when urgent diuresis is needed or when there is concern for poor gastrointestinal absorption. Continuous loop diuretic infusion is sometimes prescribed rather than intermittent bolus therapy (<a class="graphic graphic_figure graphicRef122307" href="/z/d/graphic/122307.html" rel="external">figure 2</a>). However, if a continuous infusion is used, it is important to begin with a bolus to assure that the patient is diuretic responsive and to achieve therapeutic drug concentrations. These issues are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">"Overview of the management of acute kidney injury (AKI) in adults", section on 'Hypovolemic patients'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2324.html" rel="external">"Causes and treatment of refractory edema in adults", section on 'Intravenous loop diuretic bolus therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2324.html" rel="external">"Causes and treatment of refractory edema in adults", section on 'Continuous infusion option in patients who respond to bolus therapy'</a>.)</p><p></p><p class="headingAnchor" id="H4212819663"><span class="h1">DOSING</span></p><p class="headingAnchor" id="H653258722"><span class="h2">General principles</span><span class="headingEndMark"> — </span>The effect of the loop diuretics is dose dependent, being determined largely by the rate at which the diuretic is delivered to its site of action (<a class="graphic graphic_figure graphicRef67654" href="/z/d/graphic/67654.html" rel="external">figure 3</a> and <a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">table 1</a>) [<a href="#rid2">2,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>No diuresis is seen with very low doses (ie, doses below the typical <strong>starting dose</strong>). (See <a class="local">'Starting doses'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A progressively increasing diuresis is achieved at higher doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, a plateau is reached at which even higher plasma concentrations produce minimal further diuresis; this dose is called the <strong>maximum effective dose</strong>. This maximum effective dose is higher in patients with kidney impairment (ie, patients with reduced glomerular filtration rate [GFR] require higher loop diuretic doses to achieve the maximum effect). (See <a class="local">'Maximum effective doses'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Doses higher than the maximum effective dose are sometimes used. However, dosing should not exceed the <strong>maximal recommended daily dose</strong> because of increased risk for toxicity (particularly ototoxicity, which may be irreversible). (See <a class="local">'Maximal recommended daily doses'</a> below.)</p><p></p><p>All of the loop diuretics produce the same response if given at equipotent doses. When kidney function is normal, a 40 mg dose of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> is approximately equal to 1 mg of <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a> and 20 mg of <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>. In patients with impaired kidney function, the normal dose ratio of furosemide-to-bumetanide falls from 40:1 to approximately 20:1 because of an increase in extrarenal bumetanide clearance in such patients [<a href="#rid4">4</a>].</p><p>Bioavailability of oral <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a> and <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a> is high; oral and intravenous doses of these drugs are therefore roughly equipotent. By contrast, in normal subjects, the oral bioavailability of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> is approximately 50 percent.</p><p>However, for several reasons, the response to an oral dose of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> is difficult to predict. Plasma diuretic concentrations may be sustained above the diuretic threshold for a longer period of time with oral administration, and therefore an oral dose may elicit the same natriuresis as the same intravenous dose despite the lower bioavailability [<a href="#rid3">3,5</a>]. In addition, there is substantial variability in the degree of bioavailability of oral furosemide (both between patients and within the same patient over time), making it difficult to predict the diuretic response that will occur in individual patients from dose to dose.</p><p>Patients with generalized edema (due, for example, to heart failure, the nephrotic syndrome, or kidney disease) are typically treated with daily therapy. At a given dose, net sodium loss occurs for only one to two weeks before a new steady state is achieved; in this setting, sodium intake and excretion are again equal as the effect of the diuretic is balanced by activation of counterregulatory factors that promote sodium retention, such as the renin-angiotensin system. However, selected patients with mild edema who are adherent with dietary sodium restriction can be treated with intermittent therapy as needed. (See  <a class="medical medical_review" href="/z/d/html/2307.html" rel="external">"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'The steady state'</a> and  <a class="medical medical_review" href="/z/d/html/2356.html" rel="external">"Time course of loop and thiazide diuretic-induced electrolyte complications"</a>.)</p><p class="headingAnchor" id="H2274825557"><span class="h2">Starting doses</span><span class="headingEndMark"> — </span>Typical loop diuretic starting doses vary according to the cause of edema and the presence of kidney function impairment (<a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">table 1</a>).</p><p>In normal subjects (ie, nonedematous individuals), a diuresis begins with as little as 10 mg of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> (0.25 mg <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a> or 5 mg <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>).</p><p>However, patients with edema require higher doses to achieve a diuresis. As examples, starting doses of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> are 20 mg once or twice daily in patients with heart failure and preserved kidney function (10 mg of <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a> or 0.5 mg of <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a> once or twice daily), and 40 mg once or twice daily in patients with nephrotic syndrome and preserved GFR (20 mg of torsemide or 1 mg of bumetanide once or twice daily). These higher starting doses compared with normal subjects are required because edematous patients have varying degrees of decreased kidney perfusion (which reduces drug delivery to the kidney) and increased activity of sodium-retaining forces (such as the renin-angiotensin-aldosterone system) (<a class="graphic graphic_figure graphicRef67654" href="/z/d/graphic/67654.html" rel="external">figure 3</a>).</p><p class="headingAnchor" id="H1991979269"><span class="h2">Maximum effective doses</span><span class="headingEndMark"> — </span>The maximum effective diuretic dose is typically defined as the dose that achieves the maximal peak rate of sodium excretion. This dose differs in patients with heart failure, cirrhosis, nephrotic syndrome, and reduced GFR (<a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">table 1</a>).</p><p>In normal (ie, nonedematous) subjects, the maximum effect (above which no further diuresis occurs) is attained with 40 mg given intravenously (approximately equivalent to 15 or 20 mg of <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a> and 1 mg of <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a>) [<a href="#rid2">2</a>]. However, the maximum effective dose is higher in patients with heart failure, cirrhosis, nephrotic syndrome, or kidney function impairment due to one or more of the following factors (<a class="graphic graphic_figure graphicRef67654" href="/z/d/graphic/67654.html" rel="external">figure 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>A reduction in effective renal blood flow, which decreases the delivery of drug to the kidney</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activation of the renin-angiotensin system and sympathetic nervous system, which enhance sodium reabsorption by the kidney (see  <a class="medical medical_review" href="/z/d/html/2307.html" rel="external">"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'Regulation of effective arterial blood volume'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A reduced GFR, which is associated with diminished secretion of loop diuretics by the proximal tubule, resulting from the retention of competing anions in kidney failure</p><p></p><p>In chronic kidney disease, the upward dose adjustment varies inversely with the estimated GFR [<a href="#rid2">2,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In moderate chronic kidney disease (ie, estimated GFR &gt;30 mL/min/1.73 m<sup>2</sup>), the maximum effective dose is approximately 80 mg of intravenous <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>, 2 to 3 mg of <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a>, or 20 to 50 mg of <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In more severe chronic kidney disease (ie, estimated GFR &lt;30 mL/min/1.73 m<sup>2</sup>), the maximum effective dose is approximately 200 mg of intravenous <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>, 8 to 10 mg of <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a>, or 50 to 100 mg of <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In oliguric acute kidney injury, these doses may be adjusted upward to as much as 500 mg of intravenous <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> or equivalent doses of <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a> or <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a>.</p><p></p><p class="headingAnchor" id="H3452565471"><span class="h2">Maximal recommended daily doses</span><span class="headingEndMark"> — </span>Although maximal effective doses are often sufficient to achieve therapeutic success, higher doses are recommended in some guidelines to increase natriuresis further. This is because net natriuresis is the product of both the maximal natriuretic effect and the time of natriuresis.</p><p>As a hypothetical example, if the maximal natriuresis per unit time that is induced by a loop diuretic is 20 percent of the filtered sodium load, giving a higher dose will not increase this further (ie, this is the "maximum effective dose"). However, a higher dose of the diuretic, by raising plasma concentrations, may prolong the period of time during which this maximum effective dose acts upon the kidney, thereby providing an additional <strong>net</strong> natriuretic effect.</p><p>Thus, administering a dose that is above the maximum effective dose may be an effective strategy to enhance natriuresis and has been incorporated into contemporary guidelines. However, in order to avoid toxicity, the administered dose should not exceed the "maximal recommended daily dose" (<a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H4"><span class="h1">MAJOR SIDE EFFECTS</span><span class="headingEndMark"> — </span>There are three major types of side effects related to loop diuretic use: those related to the diuresis and natriuresis, hypersensitivity reactions, and ototoxicity.</p><p class="headingAnchor" id="H5"><span class="h2">Diuresis related</span><span class="headingEndMark"> — </span>A variety of fluid and electrolyte abnormalities can result from the diuresis or from excessive diuresis. (See  <a class="medical medical_review" href="/z/d/html/2356.html" rel="external">"Time course of loop and thiazide diuretic-induced electrolyte complications"</a>.)</p><p>These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypokalemia (see  <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">"Causes of hypokalemia in adults", section on 'Diuretics'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic alkalosis (see  <a class="medical medical_review" href="/z/d/html/2331.html" rel="external">"Causes of metabolic alkalosis", section on 'Loop or thiazide diuretics'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypovolemia, hypotension, and azotemia (see  <a class="medical medical_review" href="/z/d/html/7216.html" rel="external">"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults", section on 'Causes of prerenal disease'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperuricemia (see  <a class="medical medical_review" href="/z/d/html/2380.html" rel="external">"Diuretic-induced hyperuricemia and gout"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyponatremia (primarily due to hypovolemia-induced release of antidiuretic hormone) (see  <a class="medical medical_review" href="/z/d/html/2288.html" rel="external">"Diuretic-induced hyponatremia"</a>)</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Hypersensitivity reactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">Furosemide</a>, <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a>, and <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>, which are sulfonamides, can cause hypersensitivity reactions, usually manifested as a rash or rarely acute interstitial nephritis, similar to those produced by other sulfonamide drugs.</p><p class="headingAnchor" id="H851077870"><span class="h3">Alternative loop diuretic therapy with ethacrynic acid</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9429" href="/z/d/drug information/9429.html" rel="external">Ethacrynic acid</a>, a non-sulfonamide loop diuretic, can be used in patients who develop a hypersensitivity reaction to <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>, <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a>, <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>, or a sulfonamide-based thiazide diuretic. Ethacrynic acid is rarely used in the absence of this indication because it may be more ototoxic than the sulfonamide diuretics when given in high doses; in addition, it is relatively insoluble and therefore cumbersome to administer intravenously.</p><p class="headingAnchor" id="H522067582"><span class="h3">Lack of allergic cross-reactivity with sulfonamide antimicrobials</span><span class="headingEndMark"> — </span>A separate issue is the risk of an allergic reaction to the sulfonamide-based loop diuretics in patients with known sulfonamide antibiotic allergy. There is minimal evidence of allergic cross-reactivity between sulfonamide antimicrobials and non-antimicrobials such as loop diuretics. Allergic reactions that do occur appear to be related to a predisposition to allergic reactions rather than sulfonamide cross-reactivity [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">"Sulfonamide allergy in HIV-uninfected patients", section on 'Between sulfonamide antimicrobials and nonantimicrobials'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Ototoxicity</span><span class="headingEndMark"> — </span>Loop diuretic-induced ototoxicity can lead to transient (usually lasting 30 minutes to 24 hours) or permanent deafness. Ototoxicity primarily occurs with high-dose intravenous therapy (eg, <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> doses above 240 mg/hour) or at lower doses in patients with kidney function impairment or concurrent use of other ototoxins such as aminoglycosides. <a class="drug drug_general" data-topicid="9429" href="/z/d/drug information/9429.html" rel="external">Ethacrynic acid</a>, which is rarely used, may be more ototoxic in high doses than furosemide, <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>, and <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a>.</p><p class="headingAnchor" id="H3957809229"><span class="h3">Mechanism</span><span class="headingEndMark"> — </span>The development of hearing loss is thought to be related to the intrinsic mechanism of loop diuretic action. Transport in the loop of Henle that is mediated by a Na-K-2Cl cotransporter is inhibited by loop diuretics. (See  <a class="medical medical_review" href="/z/d/html/2338.html" rel="external">"Mechanism of action of diuretics"</a>.)</p><p>A secretory isoform of this cotransporter is present in the inner ear and plays an important role in the composition of endolymph. A mouse model in which this transporter was inactivated led to reduced endolymph secretion, structural damage to the inner ear, deafness, and imbalance [<a href="#rid8">8,9</a>]. In humans, <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> effects on vestibular potential have been used to diagnose Meniere disease [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3731253216"><span class="h3">Importance of dose and rate of administration</span><span class="headingEndMark"> — </span>Ototoxicity is primarily seen in patients treated with high intravenous or oral doses of loop diuretics. In a review of 29 cases of deafness associated with <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> therapy that were reported to the US Food and Drug Administration soon after the drug was approved, intravenous furosemide was administered in 17 patients. The average rate of furosemide infusion in these patients was above 4 mg/min (240 mg/hour), and total doses administered over one to nine days ranged, in most patients, from 200 mg to 21,600 mg [<a href="#rid11">11</a>]. Therapy was usually more prolonged in the 12 patients treated with oral therapy (range 2 to 365 days), with doses ranging from 80 to 600 mg/day.</p><p>The risk of ototoxicity is also higher in patients with acute or chronic kidney disease and in those taking other potential ototoxins such as an aminoglycoside antibiotic [<a href="#rid11">11</a>]. Specifically, lower doses of loop diuretics (equivalent of 80 to 160 mg/hour [2 to 4 g/day] of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>) may result in deafness among patients with acute kidney injury [<a href="#rid12">12</a>]. Similarly, deafness has been reported with lower loop diuretic doses in patients concurrently treated with an aminoglycoside.</p><p>The risk of ototoxicity may be lower with continuous intravenous infusion rather than bolus therapy [<a href="#rid13">13,14</a>]. In a randomized, crossover trial, for example, 20 patients with severe heart failure were treated with an 8 hour continuous infusion of high-dose <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> (250 to 2000 mg, mean 690 mg) or the same dose given as a single intravenous bolus [<a href="#rid13">13</a>]. All five episodes of reversible hearing loss occurred with bolus therapy, which was associated with a significantly higher maximum serum furosemide concentration (95 versus 24 mcg/mL with the continuous infusion). Similar findings were noted in a subsequent meta-analysis of eight trials involving 254 patients with heart failure; continuous infusion was associated with a significantly lower rate of ototoxicity, defined as hearing loss or tinnitus (relative risk 0.06, 95% CI 0.01-0.44) [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H8527024"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16828.html" rel="external">"Patient education: Side effects from medicines (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11153326"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The effect of the loop diuretics is dose dependent, being determined largely by the rate at which the diuretic is delivered to its site of action (<a class="graphic graphic_figure graphicRef67654" href="/z/d/graphic/67654.html" rel="external">figure 3</a> and <a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">table 1</a>) (see <a class="local">'General principles'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No diuresis is seen with very low doses (ie, doses below the typical <strong>starting dose</strong>) (<a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">table 1</a>). In normal subjects (ie, nonedematous individuals), a diuresis begins with as little as 10 mg of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> (0.25 mg <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a> or 5 mg <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>). However, patients with edema require larger doses to achieve a diuresis. A progressively increasing diuresis is achieved at higher doses. (See <a class="local">'Starting doses'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, a plateau is reached at which even higher plasma concentrations produce minimal further diuresis; this dose is called the <strong>maximum effective dose</strong> (<a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">table 1</a>). In normal (ie, nonedematous) subjects, the maximum effect (above which no further diuresis occurs) is attained with 40 mg of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> given intravenously (approximately equivalent to 15 or 20 mg of <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a> and 1 mg of <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a>). However, the maximum effective dose is higher in patients with heart failure, cirrhosis, nephrotic syndrome, or kidney function impairment. (See <a class="local">'Maximum effective doses'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Doses higher than the maximum effective dose are included in some evidence-based guidelines because they lengthen the time above the diuretic threshold to increase net natriuresis. However, dosing should not exceed the <strong>maximal recommended daily dose</strong> because of increased risk for toxicity (particularly ototoxicity, which may be irreversible) (<a class="graphic graphic_table graphicRef120718" href="/z/d/graphic/120718.html" rel="external">table 1</a>). (See <a class="local">'Maximal recommended daily doses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All of the loop diuretics produce the same response if given at equipotent doses. When kidney function is normal, a 40 mg dose of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> is approximately equal to 1 mg of <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a> and 20 mg of <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>. In patients with impaired kidney function, the normal dose ratio of furosemide-to-bumetanide falls from 40:1 to approximately 20:1 because of an increase in extrarenal bumetanide clearance in such patients. Bioavailability of oral torsemide and bumetanide is high; oral and intravenous doses of these drugs are therefore roughly equipotent. By contrast, the bioavailability of oral furosemide in normal subjects is approximately 50 percent. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are three major types of side effects related to loop diuretic use: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Those related to the diuresis and natriuresis (including hypokalemia, metabolic alkalosis, hypovolemia, and hyperuricemia). (See <a class="local">'Diuresis related'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypersensitivity. <a class="drug drug_general" data-topicid="9429" href="/z/d/drug information/9429.html" rel="external">Ethacrynic acid</a>, a non-sulfonamide loop diuretic, can be used in patients who develop a hypersensitivity reaction to <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>, <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">bumetanide</a>, <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">torsemide</a>. There is minimal evidence of allergic cross-reactivity between sulfonamide antimicrobials and non-antimicrobials. Thus, patients with a history of allergy to sulfonamide antimicrobial drugs would be expected to tolerate nonantimicrobial sulfonamides such as loop diuretics. (See <a class="local">'Hypersensitivity reactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Loop diuretic-induced ototoxicity can lead to transient (usually lasting 30 minutes to 24 hours) or permanent deafness. Ototoxicity primarily occurs with high-dose intravenous therapy (eg, <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> doses above 240 mg/hour) or at lower doses in patients with kidney function impairment or concurrent use of other ototoxins such as aminoglycosides. (See <a class="local">'Ototoxicity'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ellison DH. Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am J Kidney Dis 1994; 23:623.</a></li><li class="breakAll">Brater DC, Voelker JR. Use of diuretics in patients with renal disease. In: Pharmacotherapy of Renal Disease and Hypertension (Contemporary Issues in Nephrology), Bennett WM, McCarron DA (Eds), Churchill Livingstone, New York 1987. Vol 17.</li><li><a class="nounderline abstract_t">Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982; 22:69.</a></li><li><a class="nounderline abstract_t">Voelker JR, Cartwright-Brown D, Anderson S, et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987; 32:572.</a></li><li><a class="nounderline abstract_t">Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. N Engl J Med 2017; 377:1964.</a></li><li><a class="nounderline abstract_t">Brater DC, Anderson SA, Brown-Cartwright D. Response to furosemide in chronic renal insufficiency: rationale for limited doses. Clin Pharmacol Ther 1986; 40:134.</a></li><li><a class="nounderline abstract_t">Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.</a></li><li><a class="nounderline abstract_t">Delpire E, Lu J, England R, et al. Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter. Nat Genet 1999; 22:192.</a></li><li><a class="nounderline abstract_t">Flagella M, Clarke LL, Miller ML, et al. Mice lacking the basolateral Na-K-2Cl cotransporter have impaired epithelial chloride secretion and are profoundly deaf. J Biol Chem 1999; 274:26946.</a></li><li><a class="nounderline abstract_t">Seo T, Node M, Yukimasa A, Sakagami M. Furosemide loading vestibular evoked myogenic potential for unilateral Ménière's disease. Otol Neurotol 2003; 24:283.</a></li><li><a class="nounderline abstract_t">Gallagher KL, Jones JK. Furosemide-induced ototoxicity. Ann Intern Med 1979; 91:744.</a></li><li><a class="nounderline abstract_t">Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol 1981; 15:90.</a></li><li><a class="nounderline abstract_t">Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28:376.</a></li><li><a class="nounderline abstract_t">Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005; :CD003178.</a></li></ol></div><div id="topicVersionRevision">Topic 2310 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8172204" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diuretic drugs and the treatment of edema: from clinic to bench and back again.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8172204" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diuretic drugs and the treatment of edema: from clinic to bench and back again.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7120755" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The time course of delivery of furosemide into urine: an independent determinant of overall response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3430953" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparison of loop diuretics in patients with chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141174" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diuretic Treatment in Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3731676" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Response to furosemide in chronic renal insufficiency: rationale for limited doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14573734" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369265" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10480906" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mice lacking the basolateral Na-K-2Cl cotransporter have impaired epithelial chloride secretion and are profoundly deaf.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12621345" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Furosemide loading vestibular evoked myogenic potential for unilateral Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/496112" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Furosemide-induced ototoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7011622" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : High dose frusemide in acute renal failure: a controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800113" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034890" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Continuous infusion versus bolus injection of loop diuretics in congestive heart failure.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
